The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia
Open accessAbstract
BACKGROUND: Severe aplastic anemia, which is characterized by immune-mediated bone marrow hypoplasia and pancytopenia, can be treated effectively with immunosuppressive therapy or allogeneic transplantation. One third of patients have disease that is refractory to immunosuppression, with persistent, severe cytopenia and a profound deficit in hematopoietic stem cells and progenitor cells. Thrombopoietin may increase the number of hematopoietic stem cells and progenitor cells. METHODS: We conducted a phase 2 study involving patients with aplastic anemia that was refractory to immunosuppression to determine whether the oral thrombopoietin mimetic eltrombopag (Promacta) can improve blood counts. Twenty-five patients received eltrombopag at a dose of 50 mg, which could be increased, as needed, to a maximum dose of 150 mg daily, for a total of 12 weeks. Primary end points were clinically significant changes in blood counts or transfusion independence. Patients with a response continued to receive eltrombopag. RESULTS: Eleven of 25 patients (44%) had a hematologic response in at least one lineage at 12 weeks, with minimal toxic effects. Nine patients no longer needed platelet transfusions (median increase in platelet count, 44,000 per cubic millimeter). Six patients had improved hemoglobin levels (median increase, 4.4 g per deciliter); 3 of them were previously dependent on red-cell transfusions and no longer needed transfusions. Nine patients had increased neutrophil counts (median increase, 1350 per cubic millimeter). Serial bone marrow biopsies showed normalization of trilineage hematopoiesis in patients who had a response, without increased fibrosis. Monitoring of immune function revealed no consistent changes. CONCLUSIONS: Treatment with eltrombopag was associated with multilineage clinical responses in some patients with refractory severe aplastic anemia. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT00922883.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Current concepts in the pathophysiology and treatment of aplastic anemia
Young, N. S., Calado, R. T., & Scheinberg, P. (2006) · Blood · doi:10.1182/blood-2006-03-010777 · Cited by 704
Self-citationAlexander, W., Roberts, A., Nicola, N., Li, R., & Metcalf, D. (1996) · Blood · doi:10.1182/blood.v87.6.2162.bloodjournal8762162 · Cited by 577
Critical Role of Thrombopoietin in Maintaining Adult Quiescent Hematopoietic Stem Cells
Qian, H., Buza-Vidas, N., Hyland, C. D., Jensen, C. T., Antonchuk, J., Månsson, R., Thoren, L. A., Ekblom, M., Alexander, W. S., & Jacobsen, S. E. W. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.10.008 · Cited by 565
Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia
Scheinberg, P., Nunez, O., Weinstein, B., Scheinberg, P., Biancotto, A., Wu, C. O., & Young, N. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103975 · Cited by 504
Self-citationEmmons, R., Reid, D., Cohen, R., Meng, G., Young, N., Dunbar, C., & Shulman, N. (1996) · Blood · doi:10.1182/blood.v87.10.4068.bloodjournal87104068 · Cited by 442
Self-citationRosenfeld, S., Follmann, D., Nunez, O., & Young, N. S. (2003) · JAMA · doi:10.1001/jama.289.9.1130 · Cited by 396
Self-citationHematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin
Kimura, S., Roberts, A. W., Metcalf, D., & Alexander, W. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1195 · Cited by 391
Historical review: megakaryopoiesis and thrombopoiesis
Kaushansky, K. (2008) · Blood · doi:10.1182/blood-2007-05-088500 · Cited by 320
Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist
Erickson-Miller, C. L., Delorme, E., Tian, S.-S., Hopson, C. B., Landis, A. J., Valoret, E. I., Sellers, T. S., Rosen, J., Miller, S. G., Luengo, J. I., et al. (2009) · Stem Cells · doi:10.1634/stemcells.2008-0366 · Cited by 285
Zeigler, F., de Sauvage, F., Widmer, H., Keller, G., Donahue, C., Schreiber, R., Malloy, B., Hass, P., Eaton, D., & Matthews, W. (1994) · Blood · doi:10.1182/blood.v84.12.4045.bloodjournal84124045 · Cited by 257
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia
Scheinberg, P., Wu, C. O., Nunez, O., & Young, N. S. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07450.x · Cited by 209
Self-citationScheinberg, P., Cooper, J. N., Sloand, E. M., Wu, C. O., Calado, R. T., & Young, N. S. (2010) · JAMA · doi:10.1001/jama.2010.1376 · Cited by 205
Self-citationThrombopoietin and Thrombopoietin Mimetics in the Treatment of Thrombocytopenia
Kuter, D. J. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.181154 · Cited by 180
Late clonal diseases of treated aplastic anemia
Socié, G., Rosenfeld, S., Frickhofen, N., Gluckman, E., & Tichelli, A. (2000) · Seminars in Hematology · doi:10.1016/s0037-1963(00)90033-7 · Cited by 173
Bona, E. D., Rodeghiero, F., Bruno, B., Gabbas, A., Foa, P., Locasciulli, A., Rosanelli, C. P., Camba, L., Saracco, P., Lippi, A., et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01693.x · Cited by 162
Maciejewski, J., Selleri, C., Sato, T., Anderson, S., & Young, N. (1996) · Blood · doi:10.1182/blood.v88.6.1983.bloodjournal8861983 · Cited by 160
Self-citationCytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes
Feng, X., Scheinberg, P., Wu, C. O., Samsel, L., Nunez, O., Prince, C. J., Ganetzky, R. D., McCoy, J. P., Maciejewski, J. P., & Young, N. S. (2010) · Haematologica · doi:10.3324/haematol.2010.030536 · Cited by 145
Self-citationSocié, G., Mary, J., Schrezenmeier, H., Marsh, J. C. W., Bacigalupo, A. P., Locasciulli, A., Führer, M., Békássy, A. N., Tichelli, A., & Passweg, J. R. (2006) · Blood · doi:10.1182/blood-2006-07-034272 · Cited by 119
Valdez, J. M., Scheinberg, P., Nunez, O., Wu, C. O., Young, N. S., & Walsh, T. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq245 · Cited by 117
Self-citationCalado, R. T., Cooper, J. N., Padilla‐Nash, H. M., Sloand, E. M., Wu, C. O., Scheinberg, P., Ried, T., & Young, N. S. (2011) · Leukemia · doi:10.1038/leu.2011.272 · Cited by 115
Self-citationGurion, R., Gafter-Gvili, A., Paul, M., Vidal, L., Ben‐Bassat, I., Yeshurun, M., Shpilberg, O., & Raanani, P. (2009) · Haematologica · doi:10.3324/haematol.2008.002170 · Cited by 74
Cited by
Young, N. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1413485 · Cited by 722
Self-citationGuidelines for the use of platelet transfusions
Estcourt, L. J., Birchall, J., Allard, S., Bassey, S. J., Hersey, P., Kerr, J. P., Mumford, A. D., Stanworth, S. J., Tinegate, H., & the British Committee for Standards in Haematology (2017) · British Journal of Haematology · doi:10.1111/bjh.14423 · Cited by 648
Modulating the stem cell niche for tissue regeneration
Lane, S. W., Williams, D. A., & Watt, F. M. (2014) · Nature Biotechnology · doi:10.1038/nbt.2978 · Cited by 615
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia
Townsley, D. M., Scheinberg, P., Winkler, T., Desmond, R., Dumitriu, B., Rios, O., Weinstein, B., Valdez, J., Lotter, J., Feng, X., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613878 · Cited by 562
Self-citationHow I treat acquired aplastic anemia
Scheinberg, P., & Young, N. S. (2012) · Blood · doi:10.1182/blood-2011-12-274019 · Cited by 443
Self-citation
Metadata
- Authors
- Olnes, M. J., Scheinberg, P., Calvo, K. R., Desmond, R., Tang, Y., Dumitriu, B., Parikh, A. R., Soto, S., Biancotto, A., Feng, X., Lozier, J., Wu, C. O., Young, N. S., & Dunbar, C. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-05
- Volume
- 367
- Issue
- 1
- Pages
- 11-19
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2106339572
- Cited by
- 539
- References
- 22
- FWCI
- 21.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.